We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Eli Lilly And Co | LSE:0Q1G | London | Ordinary Share | ELI LILLY ORD SHS |
Bid Price | Offer Price | High Price | Low Price | Open Price | |
---|---|---|---|---|---|
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
Pharmaceutical Preparations | USD 34.12B | USD 5.24B | USD 5.5202 | 145.50 | 762.45B |
Last Trade Time | Trade Type | Trade Size | Trade Price | Currency |
---|---|---|---|---|
20:33:19 | O | 18 | 63,215.981 | CHF |
Date | Time | Source | Headline |
---|---|---|---|
21/5/2024 | 13:14 | ALNC | *Eli Lilly: over half of Crohn's disease patients reach remission at 1 year.. |
15/5/2024 | 21:07 | ALNC | Eli Lilly reaches settlement with Totality Medispa |
30/4/2024 | 13:26 | ALNC | TOP NEWS: Eli Lilly lifts outlook, ramps up production to meet demand |
08/3/2024 | 15:16 | ALNC | Eli Lilly's Donanemab Alzheimer's drug hit by delays |
06/2/2024 | 12:44 | ALNC | TOP NEWS: Eli Lilly eyes beefier sales amid weight loss drug craze |
26/1/2024 | 06:04 | ALNC | Eli Lilly weight loss drug could be supplied to UK 'in weeks' |
23/1/2024 | 18:48 | ALNC | IN BRIEF: Eli Lilly hails upbeat trial data for hearing loss therapy |
17/11/2023 | 14:18 | ALNC | TOP NEWS: Eli Lilly to invest USD2.5 billion in Germany |
09/11/2023 | 06:09 | ALNC | Eli Lilly diabetes drug authorised for weight management, loss in UK |
08/11/2023 | 20:15 | ALNC | US approves highly anticipated Eli Lilly weight loss drug |
Eli Lilly (0Q1G) Share Charts1 Year Eli Lilly Chart |
|
1 Month Eli Lilly Chart |
Intraday Eli Lilly Chart |
Trade Time | Trade Price | Trade Size | Trade Value | Trade Type |
---|---|---|---|---|
06:15:20 | 63,215.98 | 18 | 0.00 | O |
06:15:11 | 63,308.92 | 5 | 0.00 | O |
06:15:11 | 63,393.26 | 3 | 0.00 | O |
06:15:11 | 63,408.81 | 1 | 0.00 | O |
06:15:11 | 63,365.91 | 7 | 0.00 | O |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions